Clinical Trial Update: Trial of Maintenance With Niraparib- Uterine Serous Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of Niraparib as maintenance therapy in uterine serous carcinoma and related endometrial cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Papillary Serous Endometrial Carcinoma
• Uterine Serous Carcinoma

Drugs mentioned

• Niraparib (Zejula) (Niraparib)

Snippet

Sponsor: Northwell Health | Conditions: Endometrial Cancer, Papillary Serous Endometrial Carcinoma | Phase 2 | Status: COMPLETED